Testing a repurposed drug for weight loss in advanced cancer
Treatments studied
This study tests whether a drug called selpercatinib can help patients with advanced lung, pancreatic, or colorectal cancer who are losing weight while on chemotherapy. It aims to see if the drug is safe and might reverse or prevent further weight loss.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have advanced lung, pancreatic, or colorectal cancer that has spread.
- You are currently receiving chemotherapy that includes a platinum drug.
- You have lost at least 5% of your body weight in the last 6 months, or at least 2% if your BMI is under 20.
- You are 18 years or older.
- You have a certain blood level of GDF-15 (a protein linked to weight loss).
- You are in relatively good health otherwise, with a life expectancy over 4 months.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new appetite-boosting medicine (nano-crystalline megestrol acetate) added to standard chemotherapy for people with advanced small cell lung cancer who are losing weight. It aims to see if it helps with weight, strength, and treatment response.
This trial tests a new drug, ASCA101, for people with certain cancers who are experiencing unwanted weight loss (cachexia). It aims to see if the drug can help improve appetite and stabilize weight. Participants must have colorectal, ovarian, or lung cancer and meet specific weight loss criteria.
This study looks at different types of weight loss (cachexia) in people with advanced lung, pancreatic, or colorectal cancer. Researchers want to find patterns to better understand and treat it. You can join even if you haven't lost weight yet.
This trial tests a combination of nanocrystalline megestrol (a medicine to improve appetite and weight) with standard chemotherapy and immunotherapy as a first treatment for people with extensive-stage small cell lung cancer who have lost weight or have early signs of cachexia (wasting syndrome). The goal is to see if this approach can help you feel better and live longer.
This study looks at how weight loss and muscle loss affect people with advanced cancer. It aims to find different types of weight loss to better guide treatment and care.
This study tests a new medicine (QLS2319) to see if it’s safe and can help people with cancer-related weight loss and muscle loss (cachexia). It’s for people whose daily activities aren’t severely limited by their cancer.
Hear when a new Cachexia-Anorexia Syndrome trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.